Initial Empiric Therapy for Fever in Neutropenia
Despite significant improvements in supportive care, infection remains a significant cause of morbidity and mortality for patients with cancer undergoing intensive chemotherapy. This is particularly important for patients with hematologic malignancies receiving induction-chemotherapy or bone marrow transplantation. Neutropenia (<1000 granulocytes/μl) is the most significant risk factor with the majority of the infections developing at a granulocyte count <500/μl and almost all the bacteremias at <100 granulocytes/μl (Bodey et al. 1966).
KeywordsOncol Beach Glycoside Gentamicin Cytosine
Unable to display preview. Download preview PDF.
- Bustamante CI, Wharton RC, Moody MA, Novak M, Talley E, Saba G, Wade JC (1986) Imipenem induced concentration dependent antagonism when combined with β-lactams. American Society of Microbiology, Washington, D.C., abstract #A95Google Scholar
- Rubin M, Hathorn JW, Marshall D et al. (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Inter Med 108: 30–35Google Scholar
- Schimpff SC (1990) Infections in the compromised host - an overview. In: Mandell GL, Douglas RG JR, Bennett JE (eds) Principles and practice of infectious diseases, 3rd edn. Churchill Livingstone, New York, pp 2258–2265Google Scholar
- Shenep JL, Hughes WT, Roberson PK, Blankenship KR, Baker DK Jr, Meyer WH, Gigliotti F, Sixbey JW, Santana VM, Feldman S et al. (1988) Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 319: 1053–1058PubMedCrossRefGoogle Scholar
- Wade JC, Standiford HC, Drusano GL, Johnson DE, Moody MR, Bustamante CI, Joshi JH, de Jongh CA, Schimpff SC (1985) Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 78: 62–72Google Scholar
- Wade JC, Bustamante CI, Devlin A, Finley R, Drusano G, Thompson B (1987) Imipenem versus piperacillin plus amikacin as empiric therapy for febrile neutropenic patients: a double blind trial. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington (abstr) 1251Google Scholar
- rHughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381–396 A concerted effort by leading members of the Infectious Diseases Society of America to design guidelines for the use of antimicrobial agents in neutropenic patients with fever.CrossRefGoogle Scholar
- Pizzo PA, Armstrong D, Bodey G et al. (1990) The design, analysis and reporting of clinical trials on the empiric antibiotic management of the neutropenic patient. J Infect Dis 161:397–401 The results of a consensus panel of the Immunocompromised Host Society to facilitate the implementation of uniform designs and analysis of empiric antibiotic trials in neutropenic cancer patients worldwide.CrossRefGoogle Scholar